Bolze Alexandre, Kiser Daniel, Schiabor Barrett Kelly M, Elhanan Gai, Schnell Blitstein Jamie M, Neveux Iva, Dabe Shaun, Reed Harry, Anderson Alexa, Metcalf William J, Orlova Ekaterina, Thibodeau Ildiko, Telis Natalie, Jiang Ruomu, Washington Nicole L, Ferber Matthew J, Hajek Catherine, Cirulli Elizabeth T, Grzymski Joseph J
Helix, San Mateo, CA.
Department of Internal Medicine, University of Nevada Reno, School of Medicine, Reno, NV.
Genet Med Open. 2024 Feb 2;2:101826. doi: 10.1016/j.gimo.2024.101826. eCollection 2024.
This study aimed to evaluate the performance of different genetic screening approaches to identify women at high risk of breast cancer in the general population.
We retrospectively studied 25,591 women with available electronic health records and genetic data, participants in the Healthy Nevada Project.
Family history of breast cancer was ascertained on or after the record of breast cancer for 78% of women with both, indicating that this risk assessment method is not being properly utilized for early screening. Genetics offered an alternative method for risk assessment. 11.4% of women were identified as high risk based on possessing a predicted loss-of-function (pLOF) variant in , , or (hazard ratio = 10.4, 95% confidence interval: 8.1-13.5) or a pLOF variant in or (hazard ratio = 3.4, CI: 2.4-4.8) or being in the top 10% of the polygenic risk score (PRS) distribution (hazard ratio = 2.4, CI: 2.0-2.8). Moreover, women with a pLOF in or and ranking in the top 50% of the PRS displayed a high risk (39.2% probability of breast cancer at age 70), whereas their counterparts in the bottom 50% of the PRS were not at high risk (14.4% probability at age 70).
Our findings suggest that a combined monogenic and polygenic approach allowed a better identification of participants with high risk while minimizing false positives.
本研究旨在评估不同基因筛查方法在识别普通人群中乳腺癌高危女性方面的性能。
我们回顾性研究了25591名拥有电子健康记录和基因数据的女性,她们均为健康内华达项目的参与者。
在同时拥有乳腺癌记录和家族史的女性中,78%的女性是在乳腺癌记录之后才确定家族史的,这表明这种风险评估方法未被妥善用于早期筛查。遗传学提供了一种风险评估的替代方法。11.4%的女性基于以下情况被确定为高危:在 、 或 中存在预测的功能丧失(pLOF)变异(风险比 = 10.4,95%置信区间:8.1 - 13.5),或在 或 中存在pLOF变异(风险比 = 3.4,置信区间:2.4 - 4.8),或处于多基因风险评分(PRS)分布的前10%(风险比 = 2.4,置信区间:2.0 - 2.8)。此外,在 或 中存在pLOF且PRS排名在前50%的女性显示为高危(70岁时患乳腺癌的概率为39.2%),而PRS排名在后50%的女性则不属于高危(70岁时概率为14.4%)。
我们的研究结果表明,单基因和多基因相结合的方法能够更好地识别高危参与者,同时将假阳性降至最低。